Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice


Por: Antolín-Novoa S, Blanco-Campanario E, Antón A, Gallegos-Sancho MI, Pérez-Carrión R, Peláez I, Galán-Brotons A, de la Cruz-Merino L, Murías-Rosales A and SmallHER Study Group

Publicada: 1 nov 2015 Ahead of Print: 24 jun 2015
Resumen:
Trastuzumab has proven to improve the prognosis of HER2-positive breast cancer, but the information available about its administration for small tumors is still limited. Therefore, we assessed the use of adjuvant regimens with trastuzumab for the treatment of small HER2-positive breast cancer in routine clinical practice. This observational study was conducted in patients with HER2-positive breast adenocarcinoma a parts per thousand currency sign1.5 cm who received trastuzumab-based adjuvant treatment in clinical practice. Clinical/histopathological data were retrieved from patients' medical charts. A total of 101 evaluable patients were enrolled (median age [range], 56.7 [49.0-64.8] years; ECOG 0, 98.0 %; ductal carcinoma, 88.1 %; lymph nodes N0, 79.2 %). Only five (5.0 %) patients received neoadjuvant treatment, while all patients underwent tumor surgery. Adjuvant trastuzumab was administered at a mean (+/- SD) dose of 5.9 +/- A 1.5 mg/kg/cycle, and mostly in a three-weekly schedule (89 [89.0 %] patients). The most frequent adjuvant therapy used with trastuzumab was chemotherapy (87 [86.1 %] patients), followed by radiotherapy (63 [62.4 %] patients) and hormone therapy (52 [51.5 %] patients). Chemotherapy regimens mainly included doxorubicin, cyclophosphamide and paclitaxel/docetaxel (n = 30), docetaxel and cyclophosphamide (n = 15), docetaxel and carboplatin (n = 13). Hormone therapy mainly included letrozole (n = 17) and tamoxifen (n = 17). Nine (8.9 %) patients reported trastuzumab-related adverse events; only one allergic reaction reached grade 3 toxicity. This study shows that trastuzumab-based adjuvant treatment of small HER2-positive breast cancer is mostly based on chemotherapy-mainly paclitaxel/docetaxel. Adjuvant administration of trastuzumab for small HER2-positive breast cancer seems to be similar to that used for larger tumors.

Direcciones
Antolín-Novoa S: Department of Oncology, Complejo Hospitalario Universitario A Coruña, Xubias de Arriba, 84, 15006, A Coruña, Spain. Silvia.Antolin.Novoa@sergas.es
Blanco-Campanario E: Department of Oncology, Hospital Infanta Cristina, Avenida de Elvas, S/N, 06080, Badajoz, Spain
Antón A: Department of Oncology, Hospital Universitario Miguel Servet, Paseo de Isabel la Católica, 1-3, 50009, Zaragoza, Spain
Gallegos-Sancho MI: Department of Oncology, Hospital General de Segovia, Carretera de Ávila, S/N, 40002, Segovia, Spain
Pérez-Carrión R: Department of Oncology, Hospital Quirón Madrid, Diego de Velázquez, 1, 28223, Pozuelo de Alarcón, Spain
Peláez I: Department of Oncology, Hospital de Cabueñes, Los Prados, 395, 33394, Gijón, Spain
Galán-Brotons A: Department of Oncology, Hospital de Sagunto, Avenida Ramón y Cajal, S/N, 46520, Sagunto, Spain
de la Cruz-Merino L: Department of Oncology, Hospital Universitario Virgen Macarena, Avenida Dr. Fedriani, 3, 41009, Seville, Spain
Murías-Rosales A: Department of Oncology, Hospital Universitario Insular de Gran Canaria, Avenida Marítima del Sur, S/N, 35016, Las Palmas de Gran Canaria, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 17 Número: 11
Páginas: 862-869s
WOS: 000363023000004
ID de PubMed: 26103952

MÉTRICAS